A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs 2 fluorofucose (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 31 Mar 2017 Last checked agaisnt ClinicalTrials.gov record.
    • 27 Mar 2017 Planned primary completion date changed from 1 May 2018 to 1 Jul 2019.
    • 09 Feb 2017 Status changed from not yet recruiting to recruiting, as reported in a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top